Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313529 | 0.92 | CNR1 (0.37) | CNR1PTGS2SLC34A1CYP2C9CYP3A4 | |
| SCHEMBL10275284 | 0.88 | SLC11A2 (0.40) | SLC11A2CCNA2CDK2PDE2ATDP2 | |
| SCHEMBL10275919 | 0.82 | CNR1 (0.38) | CNR1SLC11A2CCNA2CDK2PTGS2 | |
| SCHEMBL10275292 | 0.80 | KIF11 (0.46) | CNR1SLC11A2SLC34A1CYP3A4 | |
| SCHEMBL10275453 | 0.78 | OPRM1 (0.38) | SLC11A2CYP2C9CYP3A4CYP2C19PDE2A | |
| SCHEMBL10276440 | 0.76 | OPRM1 (0.38) | PTGS2CYP2C9CYP3A4CYP2C19PDE2A | |
| SCHEMBL10313530 | 0.74 | CNR1 (0.37) | CNR1PTGS2SLC34A1CYP2C9CYP3A4 | |
| SCHEMBL12826199 | 0.70 | CCNA2 (0.37) | CNR1SLC11A2CCNA2CDK2PTGS2 | |
| SCHEMBL10276117 | 0.69 | CNR1 (0.41) | CNR1SLC11A2SLC34A1CYP2C9CYP3A4 | |
| SCHEMBL10276231 | 0.69 | CNR1 (0.41) | CNR1SLC11A2PDE2AKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | CNR1 877/4885SLC11A2 4127/4885CCNA2 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.